As of 2025-05-16, the Fair Value of BridgeBio Pharma Inc (BBIO) is -17.59 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 33.74 USD, the upside of BridgeBio Pharma Inc is -152.13%.
With the market price of 33.74 USD and our fair value calculation, BridgeBio Pharma Inc (BBIO) is not a good investment. Investing in BridgeBio stocks now will result in a potential loss of 152.13%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 5Y Avg | |
| Net income | -448.72 | -562.54 | -481.18 | -643.20 | -535.76 | -534.28 |
| YoY growth | -72.19% | -25.37% | 14.46% | -33.67% | 16.70% | -20.01% |
| Market Cap (mil) | 6,406.55 |
| P/E | |
| Forward P/E |
| EPS | -3.52 |
| Avg earnings growth rate | -20.01% |
| TTM earnings | -667.97 |